Medigene reports financial & business results for the first nine months of 2019
(WorldNews Germany)

Martinsried/ Munich - Conference call and webcast (in English) today, 13 November 2019 at 2:00 pm CET (Munich/Frankfurt) / 8:00 am EST (New York) Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today reported on its business performance and financial results for the first nine months of 2019 and confirms the financial guidance. The full version of the quarterly statement 9M-2019 can be downloaded here: http://www.medigene.com/investors-media/reports-presentations/ Prof. Dolores Schendel, CEO/CSO of Medigene AG commented: `In the past nine months, we have continued to work intensively on the progress of our...